We claim:

1. A composition comprising

i) a sulphamate compound having a sulphamate group; and

ii) an apoptosis inducer.

2. The composition according to claim 1, wherein the apoptosis inducer is an apoptosis inducing ligand.

3. The composition according to claim 1, wherein the apoptosis inducer is an apoptosis inducing cytokine.

4. The composition according to claim 1, wherein the apoptosis inducer is a tumour necrosis factor apoptosis inducing ligand (TRAIL).

5. The composition according to claim 4, wherein the TRAIL is TRAIL/Apo-2L.

6. The composition according to claim 1, wherein the apoptosis inducer is capable of interacting with a tumour necrosis factor apoptosis inducing ligand (TRAIL) receptor.

7. The composition according to claim 6, wherein the receptor is DR4 and/or DR5.

8. The composition according to claim 1, wherein the sulphamate compound is a cyclic compound.

9. The composition according to claim 8, wherein the sulphamate compound is a polycyclic compound.

10. The composition according to claim 9 wherein the sulphamate compound is a compound having the formula:



wherein each of R_1 and R_2 is selected from the group consisting of H and a hydrocarbyl group.

11. The composition according to claim 1, wherein the sulphamate compound has a steroidal structure.

12. The composition according to claim 11, wherein the sulphamate compound is a compound having the formula:



wherein each of R_1 and R_2 is selected from the group consisting of H and a hydrocarbyl group.

13. The composition according to claim 11, wherein the sulphamate compound has at least one sulphamate group attached to the 3 position of the A ring of the steroidal nucleus.

14. The composition according to claim 1, wherein the sulphamate compound is substituted with a hydrocarbyl or an (oxy)hydrocarbyl group.

15. The composition according to claim 14, wherein the (oxy)hydrocarbyl group and the sulphamate group are each attached to the same ring, at positions ortho with respect to each other.

16. The composition according to claim 15, wherein the sulphamate compound has a steroidal structure, and wherein the (oxy)hydrocarbyl group and the sulphamate group are each attached to the A ring of the steroidal structure.

17. The composition according to claim 16, wherein the (oxy)hydrocarbyl group is attached to the 2 position of the A ring of the steroidal structure.

18. The composition according to claim 16, wherein the sulphamate group is attached to the 3 position of the A ring of the steroidal structure.

19. The composition according to claim 14, wherein the (oxy)hydrocarbyl group is a group of the formula $C_{1-6}O$.

20. The composition according to claim 19, wherein the group of the formula $C_{1-6}O$ is a methoxy group.

21. The composition according to claim 1, wherein the sulphamate compound is 2-methoxyoestrone-3-O-sulphamate.

22. The composition according to claim 14, wherein the hydrocarbyl group is a group of the formula C_{1-6}.

23. The composition according to claim 22, wherein the group of the formula C_{1-6} is an ethyl group

24. The composition according to claim 1, wherein the sulphamate compound is 2-ethyloestrone-3-O-sulphamate.

25. The composition according to claim 1, wherein the sulphamate group of the sulphamate compound has the formula:



wherein each of R_1 and R_2 is independently selected from H or a hydrocarbyl group.

26. The composition according to claim 1, wherein the sulphamate compound is an inhibitor of oestrone sulphatase (E.C. 3.1.6.2).

27. The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate compound, then the sulphate compound would be hydrolysable by a steroid sulphatase enzyme (E.C.3.1.6.2).

28. The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate compound, and the sulphate compound were incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at pH 7.4 and 37°C, it would provide a K_m value of less than 50 mM.

29. The composition according to claim 1, wherein if the sulphamate group of the sulphamate compound were to be replaced with a sulphate group to form a sulphate compound, and the sulphate compound were incubated with a steroid sulphatase enzyme (E.C.3.1.6.2) at pH 7.4 and 37°C, it would provide a K_m value of less than 50 μM.

30. The composition according to claim 1, wherein the sulphamate compound comprises at least two sulphamate groups.

31. The composition according to claim 30, wherein the sulphamate compound is steroidal.

32. The composition according to claim 1, wherein the composition further comprises a pharmaceutically acceptable carrier, diluent, or excipient.

33. A method of preventing or inhibiting growth of tumour cells comprising contacting the tumour cells with the composition of claim 1.

34. A method of inducing apoptosis of a cell comprising contacting the cell with the composition of claim 1.

35. A method of activating a caspase comprising contacting a cell comprising caspase with the composition of claim 1.

36. The method according to claim 35, wherein the caspase is caspase 3.

37. A method of upregulating receptor function of a tumour necrosis factor apoptosis inducing ligand (TRAIL) receptor, the method comprising contacting a cell comprising the TRAIL receptor with a sulphamate compound.

38. The method according to claim 37, wherein the receptor is DR4 or DR5.

39. A method of activating a caspase comprising contacting a cell comprising caspase with a sulphamate compound.

40. The method according to claim 39, wherein the caspase is caspase 3.

41. A method of treatment comprising administering to a subject in need of treatment the composition according to claim 1.

42. The method of claim 41, wherein the treatment is of cancer.

43. A method of treatment comprising inducing apoptosis by administering, to a subject in need of treatment, the composition according to claim 1 or a sulphamate compound.